Alarmed by side ef­fect, FDA slaps clin­i­cal hold on Sarep­ta's next-gen Duchenne drug

Sarep­ta Ther­a­peu­tics’ next-gen Duchenne mus­cu­lar dy­s­tro­phy drug has been hit with a clin­i­cal hold af­ter in­ves­ti­ga­tors flagged a se­ri­ous case of low mag­ne­sium lev­els in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER